ProstaScint

ProstaScint®

Capromab pendetide, see there.
References in periodicals archive ?
In the US, the company currently markets Natesto nasal formulation of testosterone for men with hypogonadism, and ProstaScint (capromab pendetide) imaging agent specific to prostate specific membrane antigen for prostate cancer detection and staging.
OTC: RSWN) has entered into an agreement with Jazz Pharmaceuticals (NASDAQ: JAZZ) to acquire Jazz Pharmaceuticals' rights to ProstaScint, an imaging agent used to detect the extent and spread of prostate cancer that is marketed in the US, the company said.
ProstaScint is a murine monoclonal antibody conjugated to a linker-chelator that targets Prostate Specific Membrane Antigen, a glycoprotein expressed by the prostate epithelium.
111]indium-labeled monoclonal antibody Prostascint to PSMA to differentiate soft tissue metastases from bone metastases, he said.
Findings of clinical studies of Prostascint have shown that the antibody scan detects soft tissue metastases more accurately than MRI or CT, but it does not detect bone metastases very well.
Bard, alleging that use of their ProstaScint product infringed United States Patent 4,460,559, which claims a method for detecting and localizing tumors.
Called ProstaScint, this MAB-radioisotope conjugate seeks and binds to PSMA molecules located on the surfaces of primary and metastatic prostate cancers.
ProstaScint Scan -- This test uses an isotope of Iridium 111 to detect the growth of prosate cancer cells outside the prostate, locally to the prostate, and throughout the body.
Currently marketed products include ProstaScint (a monoclonal antibody- based imaging agent used to image the extent and spread of prostate cancer); BrachySeed I-125 and Pd-103 (two uniquely designed, next- generation radioactive seed implants for the treatment of localized prostate cancer); and Quadramet (a skeletal targeting therapeutic radiopharmaceutical marketed for the relief of bone pain in prostate and other types of cancer).
FDA-approved products include ProstaScint (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeed(TM) I-125 and Pd-103 (uniquely designed, next-generation radioactive seed implants for the treatment of localized prostate cancer); and Quadramet (a therapeutic agent marketed for the relief of bone pain in prostate and other types of cancer).
Alaska Regional Hospital officials said theirs is the only hospital in Alaska to offer this treatment and the only site to offer ProstaScint scans, which are used to locate specific areas of prostate cancer.
A ProstaScint (capromab pendetide) examination should be considered in patients at very high risk for potential lymphatic involvement even if bone and CT scans are negative;